Drugs / 3-V Bioscience-2640
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02948569 | Feb → Dec 2017 | metabolic syndrome X | University of Missouri-Columbia | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 3-V Bioscience-2640 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02948569 ↗ |
| Action | Inhibit | “a FASN Inhibitor” NCT02948569 ↗ |
| Target | FASN | “a FASN Inhibitor” NCT02948569 ↗ |